AMI Asset Management Corp Sells 12,087 Shares of Zoetis Inc. $ZTS

AMI Asset Management Corp decreased its position in Zoetis Inc. (NYSE:ZTS) by 3.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 302,152 shares of the company’s stock after selling 12,087 shares during the period. Zoetis accounts for about 2.5% of AMI Asset Management Corp’s portfolio, making the stock its 16th largest holding. AMI Asset Management Corp’s holdings in Zoetis were worth $44,211,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in ZTS. Scott & Selber Inc. grew its stake in shares of Zoetis by 0.6% in the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after acquiring an additional 67 shares in the last quarter. North Star Asset Management Inc. grew its position in shares of Zoetis by 4.9% during the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after purchasing an additional 67 shares in the last quarter. Secure Asset Management LLC increased its holdings in shares of Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after purchasing an additional 68 shares during the period. Moment Partners LLC increased its holdings in shares of Zoetis by 3.2% during the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after purchasing an additional 72 shares during the period. Finally, CVA Family Office LLC boosted its stake in shares of Zoetis by 6.7% in the second quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after buying an additional 74 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS stock opened at $125.50 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The firm has a 50-day moving average of $127.41 and a 200-day moving average of $143.41. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.40. The company has a market cap of $55.31 billion, a P/E ratio of 21.13, a P/E/G ratio of 2.73 and a beta of 0.97.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the prior year, the firm posted $1.58 EPS. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be given a $0.53 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is presently 33.67%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ZTS shares. KeyCorp started coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating for the company. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research report on Monday, December 15th. Morgan Stanley set a $160.00 price objective on Zoetis in a report on Thursday, December 18th. Bank of America lowered Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price objective on the stock. in a research note on Monday, December 15th. Finally, BTIG Research reissued a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $160.18.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.